Floatz logo

BUSERELIN

Prostate Adenocarcinoma

NRG Oncologyprotein_peptidePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

96 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 2BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB

View all 50 →

Same molecule, other indications

BUSERELIN is also rated in:

prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
D
Indicative ·
30 / 100
View asset →
Metastatic Castration-sensitive Prostate CancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →